Asteroids Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.15 M
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 99.70%
- Profit Growth -4.93%
- Ebitda 31.77%
- Net Worth 9.73%
- Total Assets 14.04%
About Asteroids Pharmaceutical
Asteroids Pharmaceutical Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 June 2011 and has a history of 13 years and seven months. Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Shirin Gupta and Vikas Khandelwal serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232MP2011PTC026269
-
Company No.
026269
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Jun 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Asteroids Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shirin Gupta
|
Director | 28-Jun-2011 | Current |
|
Vikas Khandelwal
|
Director | 28-Jun-2011 | Current |
Financial Performance of Asteroids Pharmaceutical.
Asteroids Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 99.7% increase. The company also saw a slight decrease in profitability, with a 4.93% decrease in profit. The company's net worth moved up by a moderate rise of 9.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Asteroids Pharmaceutical?
In 2021, Asteroids Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Eureka Lifesciences Private LimitedShirin Gupta and Vikas Khandelwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Asteroids Pharmaceutical?
Unlock and access historical data on people associated with Asteroids Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Asteroids Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Asteroids Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.